Barclays maintains Inspire Medical Systems at Underweight, lowers price target to $62 from $65
Barclays lowered its price target for Inspire Medical Systems to $62 from $65, maintaining an Underweight rating. This implies a 7.8% downside from the Nov 2 close of $67.21. Recent analyst targets range from $65 to $78.
How this was made

The 30-second read
Why it matters
The downgrade could trigger short-term selling and affect related peer valuations.
Market read
Analyst target cuts are a common catalyst for price movement in small-cap stocks.
What to watch
Potential upcoming product approvals or contract wins not yet reflected in the analyst note.
Background
Barclays' research note updates its valuation and rating for Inspire Medical Systems.
Ticker impact
Barclays lowered its price target on Inspire Medical Systems to $62 from $65, maintaining an Underweight rating.
likely pressure as the market prices in the lower target
Target reduction signals weaker outlook, which typically leads to short-term sell pressure.
Market effects
May weigh on other medical device stocks as analysts reassess sector outlook.
Limited to U.S. biotech/medical device investors.
Low global impact.
Counterpoint
Some investors may view the target cut as an entry point if they believe the downgrade overstates risks.
Key entities
- Research FirmBarclays
Issued the price target reduction.
- CompanyInspire Medical Systems
Subject of the analyst downgrade.



